This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.
| AOD-9604 | Cagrilintide | |
|---|---|---|
| Highest evidence tier on the page | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. |
| Regulatory status | Not approved for human use | In clinical development, not approved |
| Research area | Metabolic and incretin | Metabolic and incretin |
| Regulator-approved dose on file | No approved dose | No approved dose |
| Molecular formula | C78H123N23O23S2 | C194H312N54O59S2, supplier data sheet only, not confirmed against a peer-reviewed or regulatory source |
| Molar mass | 1815.1 g/mol for the disulfide-cyclised form. The reduced linear form is about 1817.1, which vendor certificates sometimes quote instead. | 4409.01 g/mol average, supplier derived, not independently confirmed |
| CAS number | 221231-10-3 | 1415456-99-3, supplier derived and cross-listed on secondary references, not confirmed against a primary source |
| Registered trials on this site | 3 in the tracker | 14 in the tracker |
| Furthest registered phase | Phase 2 | Phase 3 |
| Trials currently active | 0 | 2 |
| Trial sponsors | Lateral Pharma Pty Ltd | Novo Nordisk A/S |
| Published trials covered on its page | 7 | 7 |
| Amounts studied in those trials | METAOD001: 25 to 400 micrograms per kilogram, single intravenous doses for Single doses with a 7 day washout METAOD002: 25, 50 and 100 micrograms per kilogram, single intravenous doses for Single doses with a 7 day washout METAOD004: 9, 27 or 54 mg once daily, oral for 7 days As reported on the compound page. Amounts are not comparable between compounds. | NCT03600480: Cagrilintide 0.16, 0.30, 0.60, 1.2, 2.4 or 4.5 mg once weekly or matched placebo, 3:1; every arm also received semaglutide 2.4 mg once weekly, co-escalated in 4 week intervals over 16 weeks then 4 weeks at target for 20 weeks on treatment plus 5 weeks of follow up NCT03856047: Cagrilintide 0.3, 0.6, 1.2, 2.4 or 4.5 mg once weekly, self injected, against liraglutide 3.0 mg once daily and placebo for 26 weeks including up to 6 weeks of escalation, then 6 weeks treatment free NCT04982575: Cagrilintide 2.4 mg once weekly, semaglutide 2.4 mg once weekly, or both together, 1:1:1 for 32 weeks As reported on the compound page. Amounts are not comparable between compounds. |
| What is not known | Whether it causes fat loss in a human being at any dose by any route. The 12 week study produced a signal at its lowest dose, the 24 week confirmatory study found no significant difference against placebo, and no third study was ever run. The... | What cagrilintide monotherapy does in type 2 diabetes, at arm level. The REIMAGINE 2 arm of 152 people and the four-arm chronic kidney disease trial NCT06131372 both contain monotherapy data, and neither has reached the accessible literature as arm-level numbers. What the drug does to... |
Full pages: AOD-9604 and Cagrilintide. See also the clinical trial tracker and how we grade evidence.
Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.
